Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Amberg

OncologyGrant-only

What changed

Phase II trial registered: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

6mo agoTrial registeredDec 24, 2025Source filing (opens the source filing in a new tab)

Momentum

68no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
Dec 16, 2025
Colorectal Cancer · RECRUITING · sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
ClinicalTrials.gov · NCT06722183 (opens the source filing in a new tab)
Trial
Study registered
Oct 31, 2023
Soft Tissue Sarcoma · TERMINATED · sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
ClinicalTrials.gov · NCT06050434 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 11, 2022
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement, FGFR2 Gene Translocation · TERMINATED · sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
ClinicalTrials.gov · NCT05565794 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.92{"reasons":["name similarity 100%","shared principal investigator / founder"]}
Shared principal investigator or founder links the trial record at 0.73{"reasons":["name similarity 100%","shared principal investigator / founder","same therapeutic area"]}
new_entity links the trial record at 0.27{"reasons":["same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
7mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Apr 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE2 registered

Study registered

PHASE2 registered